Clinical Trial Detail

NCT ID NCT03051659
Title A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Eribulin

Eribulin + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST